文献速递瓣膜外科

经导管二尖瓣置换术后结局与二尖瓣反流病因的关系

Outcomes After Transcatheter Mitral Valve Replacement According to Regurgitation Etiology.
PubMed 文献 · Ann Thorac Surg · 2023-09-17

基于CHOICE-MI注册研究中229例接受经导管二尖瓣置换术(TMVR)的患者,按二尖瓣反流(MR)病因为原发性、继发性或混合性分组,比较1年结局。结果显示不同MR病因组在技术成功、手术死亡率、残余MR及1年全因死亡或心衰住院复合终点上均无显著差异。

要点

  • 继发性MR占58.4%,原发性MR占28.7%,混合性MR占12.9%。
  • 不同MR病因组出院时残余MR 2+比例分别为原发性11.3%、继发性3.7%、混合性5.3%(P=0.1)。
  • 1年全因死亡率原发性28.8%、继发性24.2%、混合性32.1%(P=0.07),复合终点无差异。

核心结论

  • 在本研究中,未发现经导管二尖瓣置换术后短期和1年结局因二尖瓣反流病因不同而存在差异。

研究设计与样本

  • CHOICE-MI注册研究中746例患者里229例(30.7%)接受TMVR,按原发性、继发性或混合性MR分组,排除二尖瓣环钙化患者。

主要发现

  • 主要MR病因为继发性MR(58.4%),其次为原发性MR(28.7%)和混合性MR(12.9%)。
  • 技术成功和手术死亡率按MR病因相似。
  • 出院超声显示残余MR 2+在原发性、继发性和混合性MR患者中分别为11.3%、3.7%和5.3%(P=0.1)。
  • 所有组至1年随访时MR消除情况相似。
  • 1年全因死亡率在原发性、继发性和混合性MR患者中分别为28.8%、24.2%和32.1%(P=0.07)。

关键数值与推荐

  • 主要终点为1年全因死亡或心衰住院的复合终点,按MR病因无差异。
  • 次要终点包括1年全因和心血管死亡率、纽约心脏协会功能分级及出院和1年时的残余MR。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Whether transcatheter mitral valve replacement (TMVR) devices perform similarly with respect to the underlying mitral regurgitation (MR) etiology remains unknown. The aim of the present analysis was to assess outcomes of TMVR according to the MR underlying etiology among the CHoice of OptImal transCatheter trEatment for Mitral Insufficiency (CHOICE-MI) registry. METHODS: Of 746 patients, 229 patients (30.7%) underwent TMVR. The study population was subdivided according to primary, secondary, or mixed MR. Patients with mitral annular calcification were excluded. The primary study endpoint was a composite endpoint of all-cause mortality or hospitalization for heart failure at 1 year. Secondary study endpoints were all-cause and cardiovascular mortality at 1 year, New York Heart Association functional class, and residual MR, both at discharge and 1 year. RESULTS: The predominant MR etiology was secondary MR (58.4%), followed by primary MR (28.7%) and mixed MR (12.9%). Technical success and procedural mortality were similar according to MR etiology. Discharge echocardiography revealed residual MR 2+ in 11.3%, 3.7%, and 5.3% of patients with primary, secondary, and mixed MR, respectively (P = .1). MR elimination was similar in all groups up to the 1-year follow-up. There was no difference in terms of primary combined outcome occurrence according to MR etiology. One-year all-cause mortality was reported in 28.8%, 24.2%, and 32.1% of patients with primary, secondary, and mixed MR, respectively (P = .07). CONCLUSIONS: In our study we did not find differences in short-term and 1-year outcomes after TMVR according to MR etiology.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Perrin N, Ben-Ali W, Ludwig S, et al. Outcomes After Transcatheter Mitral Valve Replacement According to Regurgitation Etiology. Ann Thorac Surg. 2023. PMID: 37717882. doi:10.1016/j.athoracsur.2023.08.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。